Aparna Raj Parikh

Feb 29, 2024 | cancernetwork.com | John Strickler |Aparna Raj Parikh |Stacey Cohen |Arvind Dasari |Michael Foote

2 Commerce Drive Cranbury, NJ 08512

Feb 22, 2024 | cancernetwork.com | John Strickler |Aparna Raj Parikh |Stacey Cohen |Arvind Dasari |Michael Foote

2 Commerce Drive Cranbury, NJ 08512

Feb 15, 2024 | cancernetwork.com | John Strickler |Aparna Raj Parikh |Stacey Cohen |Arvind Dasari |Michael Foote

2 Commerce Drive Cranbury, NJ 08512

Jun 5, 2023 | cancernetwork.com | Cathy Eng |Suneel Kamath |Michael Foote |Arvind Dasari |Aparna Raj Parikh

Transcript:Cathy Eng, MD, FACP, FASCO: We’ve had a really great discussion today. But before we close, I’d love to get the opinion of all of you regarding unmet needs and colorectal cancer and future perspectives. So, Dr Kamath, I’m going to give you the first opportunity to answer that question of what you believe is an unmet need and future perspectives. Suneel Kamath, MD: Definitely.

May 29, 2023 | cancernetwork.com | Cathy Eng |Suneel Kamath |Michael Foote |Arvind Dasari |Aparna Raj Parikh

Transcript:Cathy Eng, MD, FACP, FASCO: I know everyone’s an expert on circulating tumor DNA [ctDNA], but I also know 2 of you have some big trials regarding circulating tumor DNA. So, can you tell me how you incorporate it in your current treatment landscape? I know you have your Stand Up to Cancer study, and obviously, you have your big phase 3 CIRCULATE-US (NCT05174169) trial, as well.